New COVID-19 Vaccine Codes: February Update

In January, a new Current Procedural Terminology (CPT®) code (0073A) for the administration of a third-dose of the Pfizer’s tris-sucrose formulation vaccine product to address severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) in pediatric patients ages 5 through 11 years who are immunocompromised was established. The CPT Editorial Panel (the Panel) has approved a new vaccine product code (91308) and its associated vaccine administration codes (0081A, 0082A) for the Pfizer tris-sucrose formulation vaccine product for pediatric patients ages 6 months through 4 years, which will become effective upon receiving the emergency use authorization from the Food and Drug Administration.

In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes) that features timely updates of the Panel’s actions. The last COVID-19 update was in the CPT® Assistant Special Edition: January Update (2022) in which the Pfizer tris-sucrose third-dose administration code (0073A) for immunocompromised pediatric patients ages 5 through 11 years was discussed.

This issue of CPT® Assistant Special Edition introduces and provides guidance on the appropriate use of the new pediatric Pfizer vaccine product (91308) and its associated vaccine administration codes (0081A, 0082A).

Immunization Administration for Vaccines/Toxoids

#0081A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

#0082A second dose

►(Report 0081A, 0082A, for the administration of vaccine 91308)
Vaccines, Toxoids

**#91308** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

(Do not report 0081A, 0082A in conjunction with 91300, 91305, 91307)

Code 91308 describes Pfizer’s pediatric-tailored COVID-19 vaccine product for patients ages 6 months through 4 years. In contrast to the pediatric formulation for ages 5 through 11 years that uses a 10 mcg/0.2 mL ready-to-use formula, the pediatric-tailored vaccine for patients ages 6 months through 4 years requires reconstitution using a diluent to reach the appropriate dosage of 3 mcg/0.2 mL. This vaccine product has a two-dose administration schedule (0081A, 0082A). The vaccine schedule specifies that the second dose is to be administered 21 or more days after administration of the first dose. As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit and should not be reported separately. The physician or other qualified health care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given pediatric patient. More information on current guidance from the Centers for Disease Control and Prevention (CDC) regarding which pediatric patients should receive a COVID-19 vaccine is available at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html.

Note that vaccine administration codes 0081A and 0082A are not intended to be reported in conjunction with the initial Pfizer vaccine product code (91300), the ready-to-use formulation designated for ages 12 or older vaccine product code (91305), or the ready-to-use formulation designated for ages 5 through 11 years vaccine product code (91307). Parenthetical notes have been added following the administration codes and product codes to clarify the appropriate use of these new vaccine administration codes.

To accommodate the new coding structure, Appendix Q was added to the CPT code set. Appendix Q details the vaccine codes, their associated vaccine administration code(s), the vaccine manufacturers and names, the National Drug Code (NDC) labeler product ID, and dosing intervals. The new Pfizer pediatric vaccine product (91308) and vaccine administration codes (0081A, 0082A) have also been added to Appendix Q.


The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

**Clinical Example (91308)**

A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

**Description of Procedure (91308)**

The physician or other qualified health care professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

**Clinical Example (0081A)**

A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular
injection of SARS-CoV-2 vaccine for the child for this purpose.

**Description of Procedure (0081A)**

The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the first dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.

**Clinical Example (0082A)**

A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

**Description of Procedure (0082A)**

The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the second dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.

**Q&A**

**Question:** What are the appropriate codes to report when administering a booster dose of a COVID-19 vaccine product to patients ages 12 years or older who are moderately to severely immunocompromised?

**Answer:** Current COVID-19 vaccine booster-dose codes may be used to report the booster dose for moderately to severely immunocompromised patients ages 12 years or older. For this patient population, the booster dose would be administered after either the third dose of the primary series of the Pfizer or Moderna product or the single-dose Janssen vaccine product has been received. Depending on which COVID-19 vaccine product is administered (based on current CDC recommendations), the administration of the booster dose should be reported with vaccine product code 91300 and vaccine administration code 0004A, vaccine product code 91305 and vaccine administration code 0054A, or vaccine product code 91306 and vaccine administration code 0064A. More information on current guidance from the CDC regarding COVID-19 vaccinations for moderately to severely immunocompromised patients is available at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.